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Conclusion: The prevalence of the inflammatory Bact2 enterotype 
was 5- to 10-fold higher in CD and UC patients as compared with 
controls. Although initiation of biological therapies leads to a de-
crease in inflammation levels as witnessed by faecal calprotectin and 
increase in microbial richness, a shift in enterotypes did not occur.
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Background: Anti-drug antibodies can affect biopharmaceutical 
pharmacokinetics by increasing or decreasing drug clearance. Drug-
tolerant (total), unlike drug-sensitive (free), antibody assays permit 
antibodies to be measured in the presence of a drug. We sought to 
confirm the positivity threshold of our total anti-tumour necrosis fac-
tor (TNF) antibody ELISA assays in a sample of healthy volunteers 
and to use this threshold to report the prevalence of clearing and tran-
sient antibodies in patients treated with infliximab and adalimumab.
Methods: Serum was obtained from a random sample of 498 anti-
TNF-naïve healthy adults recruited to the Exeter Ten Thousand study 
and tested for total anti-drug antibodies to infliximab and adalimumab. 
Using recommendations for confirmatory anti-drug antibody valid-
ation, we used bootstrapping to calculate the 80% one-sided lower 
confidence interval [CI] of the 99th centile to define assay thresholds.
We used paired drug and anti-drug antibody levels derived from our 
national therapeutic drug monitoring service to report the distribu-
tion of clearing (antibody positive, drug negative) vs. non-clearing 
(antibody positive, drug positive) antibodies. In patients with at least 
two test results, antibodies were classified as transient (single posi-
tive test with subsequent negative test) or persistent (at least two 
positive tests).
Results: The 80% one-sided lower CI of the 99th centile titre for total 
anti-drug antibody to infliximab and adalimumab were 8.7 AU/ml 
and 5.9 AU/ml, respectively. Using the manufacturer’s recommended 
threshold of 10 AU/ml for both total anti-TNF antibody assays, in 
healthy individuals, the prevalence of positive antibodies to inflixi-
mab and adalimumab was 1% (5/498) and 0.2% (1/498), respect-
ively. Using the manufacturer’s threshold, at the time of last testing, 
of 7447 and 4054 patients treated with infliximab and adalimumab; 
20.9% (n = 1,554) and 8.0% (n = 326) had clearing antibodies and 
26.5% (n = 1973) and 12.1% (n = 490) had non-clearing antibod-
ies, respectively (Figure 1). Using our newly defined threshold in the 
same cohorts; 21.1% (n  =  1573) and 8.4% (n = 339)  had clear-
ing antibodies and 28.0% (n  =  2083) and 20.0% (n  =  812) had 
non-clearing antibodies, to infliximab and adalimumab, respectively. 
Amongst patients with at least two tests, most developed persistent 
antibodies (Figure 2). Irrespective of anti-TNF drug, or threshold 
used, less than 10% patients developed transient antibodies.
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Conclusion: We report lower positivity thresholds for the 
IDKmonitor® total anti-TNF antibody ELISA assays than the 
manufacturer, in particular, for adalimumab. Transient antibody 
formation is uncommon: most patients develop persistent anti-drug 
antibodies that lead to drug clearance.
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Background: Dietary therapy with the Crohn’s disease Exclusion Diet 
(CDED) or Exclusive Enteral Nutrition (EEN) induces remission, 
reduces inflammation and is associated with compositional changes 
in the microbiome. We performed metagenome analysis to elucidate 
whether diet induces remission via correction of dysbiosis and/or 
community structure.
Methods: Whole metagenome and 16S rDNA sequences were 
obtained in 178 samples from 70 participants at 3 time points (base-
line, week 6, week 12)  from the two study groups (CDED+PEN/
EEN). For metagenome analysis, we divided the groups further into 
samples of patients achieving ITT-remission at week 6 (CDED+PEN: 
31/38 and EEN: 23/32) and those who did not.
Results: Dietary therapy decreased the relative abundance of genera 
from Proteobacteria towards healthy controls. CDED+PEN remis-
sion is associated with a significant increase (p < .05) in Clostridiales, 
and a significant decrease (p < .05) in Proteobacteria (particularly 
Γproteobacteria). Microbiome comparison of all baseline CD sam-
ples with healthy controls showed significant (p < .05) increases in 
Proteobacteria in an active CD at baseline. Healthy controls had 
increased Firmicutes species notably Roseburia, Oscillibacter and 
Anaerostipes, as well as increased Bacteroides and Ascomycota (driven 
by Saccharomyces). Proteobacteria decreased when diet-induced remis-
sion was achieved (with either CDED+PEN or EEN) at week 6: rela-
tive abundance of Proteobacteria (including Α- and Γproteobacteria 
(e.g. Escherichia, Klebsiella and Citrobacter) were significantly lower 
compared with baseline but were still more abundant in CD patients, 
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